ASCENDIS PHARMA A/S - ADR (ASND)
US04351P1012 - ADR
ASCENDIS PHARMA A/S - ADR
NASDAQ:ASND (9/18/2024, 3:21:06 PM)
149.35
+2.76 (+1.88%)
Company Profile
Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. The firm produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The firm operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).
Company Info
ASCENDIS PHARMA A/S - ADR
Tuborg Boulevard 12
Hellerup 2900
P: 4570222244
CEO: Jan Moller Mikkelsen
Employees: 879
Website: https://ascendispharma.dk/
ASND News
2 days ago - ChartmillThe market is buzzing with gapping stocks on Monday. Let's uncover which stocks are experiencing notable gaps during today's session.Gapping stocks in Monday's session
2 days ago - Investor's Business DailyAscendis Rockets — And Hammers BioMarin — On New Results For Growth DrugThe companies could soon face off in the growth treatment market for children with a genetic disorder.
2 days ago - Ascendis PharmaPivotal ApproaCH Trial of TransCon™ CNP (Navepegritide) Achieved Primary Objective, Demonstrated AGV Superior to Placebo– TransCon CNP demonstrated AGV superior to placebo with LS mean treatment difference of 1.49 cm/year at Week 52 (p<0.0001) – For children aged...
5 days ago - Ascendis PharmaAscendis to Present First Results from Platinum-Resistant Ovarian Cancer (PROC) Cohort of the Phase 1/2 IL-Believe Trial at ESMO 2024Anti-tumor clinical responses were observed in 29% (4/14) of efficacy-evaluable patients with PROC treated with TransCon IL-2 β/γ in combination with...
7 days ago - Ascendis PharmaAscendis Pharma Receives Orphan Drug Exclusivity in the U.S. for YORVIPATH® (Palopegteriparatide) for the Treatment of Hypoparathyroidism in Adults– U.S. FDA Orphan Drug exclusivity provides seven years of market exclusivity for YORVIPATH in the United States for the treatment of hypoparathyroidism...
14 days ago - The Motley FoolWhy Ascendis Pharma Stock Tumbled by 11% TodayA bottom-line whiff and reduced guidance made the company an outlier for the wrong reasons on Hump Day.
ASND Twits
Here you can normally see the latest stock twits on ASND, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
